McKhann Chas 4
4 · Silk Road Medical Inc · Filed Sep 18, 2024
Insider Transaction Report
Form 4
McKhann Chas
DirectorChief Executive Officer
Transactions
- Disposition to Issuer
Common Stock
2024-09-17−1,299,042→ 0 total - Disposition to Issuer
Common Stock
2024-09-17−722,396→ 0 total - Award
Common Stock
2024-09-17+1,299,042→ 1,299,042 total
Footnotes (4)
- [F1]The reported shares are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.
- [F2]Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) $27.50 per unit in cash (the "Merger Consideration") and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.
- [F3]Immediately prior to the effective time of the merger, certain RSUs subject to the achievement of performance-based criteria, or PSUs, were deemed achieved and certified by the Issuer's compensation committee.
- [F4]Pursuant to the Merger Agreement, each PSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the PSUs, less applicable taxes and authorized deductions.